The first and only FDA-approved treatment for severe alopecia areata in both adults and adolescents as young as 12.1-4
The first and only FDA-approved treatment for severe alopecia areata in both adults and adolescents as young as 12.1-4
See how LITFULO helped patients with severe alopecia areata1
See the pooled safety data from multiple clinical studies for LITFULO
See recommended testing and evaluations prior to initiation
See recommended testing and evaluations prior to initiation
Find personalized resources and support for patients
LITFULO is a kinase inhibitor—it inhibits JAK3 and the TEC kinase family pathways1,2,5
Register or sign in to check availability and request samples
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.